Telix Pharmaceuticals has signed a distribution agreement with Eczacıbaşı-Monrol of Istanbul.
Under the agreement, Eczacıbaşı-Monrol will be a radiopharmaceutical production partner and distributor for Telix in Turkey, the Middle East, and North Africa. The two firms will initially focus on developing TLX250-CDx (Zr-89 girentuximab) for PET imaging of renal cell carcinoma, according to Telix.
